Afatinib’s observed clinical benefit in our patient, despite the absence of classical EGFR mutations, underscores the need for further study and continued documentation of real-world responses to these emerging agents. Prospective studies and collaborative registry-based data collection efforts will be critical to improving evidence-based management of rare tumors like chordoma. The gene discussed is EGFR; the disease is chordoma.